The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Discontinuation symptoms in depression and anxiety disorders
Open accessAbstract
The present overview investigates whether different antidepressants have differing discontinuation symptoms upon treatment cessation, if these symptoms vary between depression and anxiety disorders, and with length of treatment. Data came from two comparative studies of escitalopram in major depressive disorder (MDD) (one vs. venlafaxine XR and one vs. paroxetine), two studies in social anxiety disorder (SAD) (one of which used paroxetine as the active reference), and one study in generalized anxiety disorder (GAD), using paroxetine as an active reference [total number of patients: escitalopram (n=1051); paroxetine (n=336); venlafaxine XR (n=124); placebo (n=239)]. All studies included a defined discontinuation period and used the Discontinuation Emergent Signs and Symptoms (DESS) checklist to record the number of discontinuation symptoms. All three antidepressants showed more discontinuation symptoms compared with placebo (p<0.001). Patients reported significantly fewer discontinuation symptoms with escitalopram than with paroxetine and venlafaxine XR in MDD (p<0.05). Escitalopram showed significantly fewer discontinuation symptoms than paroxetine in SAD (p<0.05) and GAD (p<0.001). For each antidepressant, no differences in discontinuation symptoms were observed between the three indications and there was no evidence for increased symptom incidence with increased length of treatment. Thus, discontinuation profiles differ between antidepressants of the same class and are broadly similar in different disorders. No evidence was seen for a higher discontinuation burden with longer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The DESS has been used for the assessment of treatment-related side-effects in ID populations [310, 311] and, recently, has been employed to monitor adverse-effects specifically associated with NFB therapy [312].”
From Infraslow closed-loop brain training for anxiety and depression (ISAD): a protocol for a randomized, double-blind, sham-controlled pilot trial in adult females with internalizing disorders (2022) · cites this paper as [311]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Self-citationSelective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial
Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00126-7 · Cited by 574
Escitalopram versus citalopram: the surprising role of the R-enantiomer
S�nchez, C., B�ges�, K. P., Ebert, B., Reines, E. H., & Bræstrup, C. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1865-z · Cited by 251
Antidepressant Discontinuation Syndromes: Clinical Relevance, Prevention and Management
Haddad, P. M. (2001) · Drug Safety · doi:10.2165/00002018-200124030-00003 · Cited by 214
Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria.
(2000) · PubMed Central · Cited by 207
Emergence of Adverse Events Following Discontinuation of Treatment With Extended-Release Venlafaxine
D, M. F. M., Mulroy, R., Alpert, J. E., Nierenberg, A. A., & Rosenbaum, J. F. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.12.1760 · Cited by 198
Montgomery, S. A., Kennedy, S. H., Burrows, G. D., Lejoyeux, M., & Hindmarch, I. (2004) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000137184.64610.c8 · Cited by 196
Self-citationMichelson, D., Fava, M., Amsterdam, J., Apter, J., Londborg, P., Tamura, R., & Tepner, R. G. (2000) · British Journal of Psychiatry · doi:10.1192/bjp.176.4.363 · Cited by 181
Bielski, R. J., Ventura, D., & Chang, C.-C. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0906 · Cited by 178
Lader, M., Stender, K., Bürger, V., & Nil, R. (2004) · Depression and Anxiety · doi:10.1002/da.20014 · Cited by 163
Self-citation
Research works printed but not linked: 2
- Baldwin DS, Hindmarch I, Huusom AKT, Cooper J (2004a). Escitalopram and paroxetine in the short and long-term treatment of major depressive disorder (MDD). International Journal of Neuropsychopharmacology 7 (Suppl. 2), S168-S169.
- Michelson D, Fava M, Amsterdam J, Apter J, Londborg P, Tamura R, Tepner RG (2000). Interruption of selective serotonin reuptake inhibitor treatment. British Journal of Psychiatry 176, 363-368.
Cited by
Sorted by citations
The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future
Carhart-Harris, R. L., & Goodwin, G. M. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.84 · Cited by 706
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676
Self-citationMalhi, G. S., Bell, E., Bassett, D., Boyce, P., Bryant, R., Hazell, P., Hopwood, M., Lyndon, B., Mulder, R., Porter, R., et al. (2021) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867420979353 · Cited by 614
Agomelatine, the first melatonergic antidepressant: discovery, characterization and development
de Bodinat, C., Lemaître, B. J., Mocaër, E., Renard, P., Muñoz, C., & Millan, M. J. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3140 · Cited by 617
Kennedy, S. H., Lam, R. W. M., Parikh, S. V., Patten, S. B., & Ravindran, A. V. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.043 · Cited by 529
Sarris, J. J., Panossian, A., Schweitzer, I., Stough, C. K. K., & Scholey, A. B. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.04.002 · Cited by 492
Lam, R. W., Kennedy, S. H., Grigoriadis, S., McIntyre, R. S., Milev, R., Ramasubbu, R., Parikh, S. V., Patten, S. B., & Ravindran, A. V. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.041 · Cited by 431
A comparative review of escitalopram, paroxetine, and sertraline: are they all alike?
Sanchez, C., Reines, E. H., & Montgomery, S. A. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000023 · Cited by 295
Self-citationHydroxyzine for generalised anxiety disorder
Guaiana, G., Barbui, C., & Cipriani, A. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006815.pub2 · Cited by 283
Escitalopram Therapy for Major Depression and Anxiety Disorders
Baldwin, D. S., Reines, E. H., Guiton, C., & Weiller, E. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1k089 · Cited by 228
Self-citationBareggi, S. R., Mundo, E., Dell’Osso, B. M., & Altamura, A. C. (2007) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425225.3.5.741 · Cited by 178
Evidence-based pharmacological treatment of generalized anxiety disorder
Baldwin, D. S., Waldman, S., & Allgulander, C. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710001434 · Cited by 183
Self-citationThe mechanisms of tolerance in antidepressant action
Fava, G. A., & Offidani, E. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.07.026 · Cited by 158
Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms
Simon, J. A., Portman, D. J., Kaunitz, A. M., Mekonnen, H., Kazempour, K., Bhaskar, S., & Lippman, J. S. (2013) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e3182a66aa7 · Cited by 146
Depression and Its Phytopharmacotherapy—A Narrative Review
Dobrek, Ł., & Głowacka, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054772 · Cited by 168
Montgomery, S. A., Nielsen, R. Z., Poulsen, L. H., & Häggström, L. (2014) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2424 · Cited by 143
“Discontinuation symptoms are normally maximal in the first week and return to close to the placebo level by the second week (Montgomery et al., 2004; Baldwin et al., 2007).”
BackgroundSelf-citationSilexan in anxiety disorders: Clinical data and pharmacological background
Kasper, S. F., Müller, W. E., Volz, H., Möller, H., Koch, E., & Dienel, A. (2017) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1331046 · Cited by 140
Evidence-based pharmacotherapy of Generalized Anxiety Disorder
Baldwin, D. S., & Polkinghorn, C. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145704004870 · Cited by 132
Self-citationAntidepressant Withdrawal and Rebound Phenomena
Henssler, J., Heinz, A., Brandt, L., & Bschor, T. (2019) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2019.0355 · Cited by 50
Renoir, T. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00045 · Cited by 107
Recognising and managing antidepressant discontinuation symptoms
Haddad, P. M., & Anderson, I. M. (2007) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.105.001966 · Cited by 109
A review of the management of antidepressant discontinuation symptoms
Wilson, E., & Lader, M. (2015) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125315612334 · Cited by 103
Self-citationSartorius, N., Baghai, T. C., Baldwin, D. S., Barrett, B. M., Brand, U., Fleischhacker, W., Goodwin, G. M., Grunze, H., Knapp, M. R. J., Leonard, B. E., et al. (2007) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707008255 · Cited by 103
Self-citationRational Use of Antidepressant Drugs
Fava, G. A. (2014) · Psychotherapy and Psychosomatics · doi:10.1159/000362803 · Cited by 95
Sarris, J. J., Moylan, S., Camfield, D., Pase, M. P., Mischoulon, D., Berk, M., Jacka, F. N., & Schweitzer, I. (2012) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2012/809653 · Cited by 104
5-HT2 ligands in the treatment of anxiety and depression
Quesseveur, G., Nguyen, H. T., Gardier, A. M., & Guiard, B. P. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.719872 · Cited by 87
Escitalopram prevents relapse of obsessive-compulsive disorder
Fineberg, N. A., Tonnoir, B., Lemming, O. M., & Stein, D. J. (2007) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2006.11.005 · Cited by 85
Estimating Risk of Antidepressant Withdrawal from a Review of Published Data
Horowitz, M. A., Framer, A., Hengartner, M. P., Sørensen, A., & Taylor, D. (2023) · CNS Drugs · doi:10.1007/s40263-022-00960-y · Cited by 76
(2022) · doi:10.1192/bja.2021.62 · Cited by 73
New insights on the antidepressant discontinuation syndrome
Harvey, B. H., & Slabbert, F. N. (2014) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2429 · Cited by 62
Drug-induced tremor, clinical features, diagnostic approach and management
Baizabal‐Carvallo, J. F., & Morgan, J. C. (2022) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2022.120192 · Cited by 61
Millan, M. J., Marin, P., Kamal, M. T., Jockers, R., Chanrion, B., Labasque, M., Bockaert, J., & la Cour, C. M. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710001045 · Cited by 60
Chen, X., van Gerven, J., Cohen, A. F., & Jacobs, G. E. (2018) · Acta Pharmacologica Sinica · doi:10.1038/s41401-018-0185-5 · Cited by 58
Discontinuation of psychotropic medication: a synthesis of evidence across medication classes.
Vinkers, C. H., Kupka, R. W., Penninx, B. W., Ruhé, H. G., van Gaalen, J. M., van Haaren, P. C. F., Schellekens, A. F. A., Jauhar, S., Ramos-Quiroga, J. A., Vieta, E., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02445-4 · Cited by 51
Monoamine Oxidase Inhibitors (MAOIs) in Psychiatric Practice: How to Use them Safely and Effectively
Chamberlain, S. R., & Baldwin, D. S. (2021) · CNS Drugs · doi:10.1007/s40263-021-00832-x · Cited by 50
Self-citationAntidepressant withdrawal – the tide is finally turning
Hengartner, M. P., Davies, J., & Read, J. (2020) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796019000465 · Cited by 48
Narayan, V., & Haddad, P. M. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881109359094 · Cited by 48
The use of antidepressants in clinical practice: focus on agomelatine
McAllister-Williams, H., Baldwin, D. S., Haddad, P. M., & Bazire, S. (2010) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1094 · Cited by 49
Self-citationAtypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disorders
Gao, K., Sheehan, D. V., & Calabrese, J. R. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.37 · Cited by 41
Pharmacotherapy of Mood Disorders and Treatment Discontinuation
LADER, M. H. (2007) · Drugs · doi:10.2165/00003495-200767120-00001 · Cited by 39
Self-citationBarić, H., Đorđević, V., Cerovečki, I., & Trkulja, V. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0680-6 · Cited by 40
Antidepressants, suicidality and rebound effect: evidence of similitude?
Teixeira, M. Z. (2009) · Homeopathy · doi:10.1016/j.homp.2009.02.004 · Cited by 39
Baek, J. H., Nierenberg, A. A., & Kinrys, G. (2014) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867414539198 · Cited by 39
Antidepressant withdrawal symptoms—Telephone calls to a national medication helpline
Taylor, D., Stewart, S., & Connolly, A. (2006) · Journal of Affective Disorders · doi:10.1016/j.jad.2006.04.026 · Cited by 37
Murata, Y., Kobayashi, D., Imuta, N., Haraguchi, K., Ieiri, I., Nishimura, R., Koyama, S., & Mine, K. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181c8ae80 · Cited by 37
Pharmacological Treatment of Generalized Anxiety Disorder
Baldwin, D. S., Ajel, K. I., & Garner, M. J. (2009) · Current topics in behavioral neurosciences · doi:10.1007/7854_2009_2 · Cited by 39
Self-citationTreatment of anxiety disorders with venlafaxine XR
Thase, M. E. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.3.269 · Cited by 37
Mao, J. J. J., & Li, Q. S. (2015) · Journal of Clinical Trials · doi:10.4172/2167-0870.1000188 · Cited by 36
Efeito rebote dos fármacos modernos: evento adverso grave desconhecido pelos profissionais da saúde
Teixeira, M. Z. (2013) · Revista da Associação Médica Brasileira · doi:10.1016/j.ramb.2013.05.003 · Cited by 43
Antidepressants, withdrawal, and addiction; where are we now?
Jauhar, S., Hayes, J., Goodwin, G. M., Baldwin, D. S., Cowen, P. J., & Nutt, D. J. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119845799 · Cited by 31
Self-citationPredictors of premature discontinuation of treatment in multiple disease states
Nantz, E., Liu-Seifert, H., & Skljarevski, V. (2009) · Patient Preference and Adherence · doi:10.2147/ppa.s4633 · Cited by 29
Montgomery, S. A., Fava, M., Padmanabhan, S. K., J. Guico-Pabia, C., & Tourian, K. A. (2009) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32832fbb5a · Cited by 27
Self-citationSSRIs and SNRIs: A review of the Discontinuation Syndrome in Children and Adolescents.
Hosenbocus, S., & Chahal, R. (2011) · PubMed Central · Cited by 27
Kious, B. M., Sabic, H., Sung, Y., Kondo, D. G., & Renshaw, P. F. (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000754 · Cited by 26
Ou, J., Xun, G., Wu, R., Li, L., Fang, M., Zhang, H., Xie, S., Shi, J., Du, B., Yuan, X.-Q., et al. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1822-y · Cited by 27
Developmentally Informed Pharmacotherapy for Child and Adolescent Depressive Disorders
Sakolsky, D. J., & Birmaher, B. B. (2012) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2012.01.005 · Cited by 26
LADER, M. H. (2015) · Springer eBooks · doi:10.1007/978-3-642-36172-2_317 · Cited by 25
Self-citationJauhar, S., & Hayes, J. (2019) · Addictive Behaviors · doi:10.1016/j.addbeh.2019.01.025 · Cited by 23
Hengartner, M. P., & Plöderl, M. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211032051 · Cited by 23
Go, A. C., Golightly, L. K., Barber, G. R., & Barron, M. A. (2010) · Drug metabolism and drug interactions · doi:10.1515/dmdi.2010.001 · Cited by 23
Horowitz, M. A., Buckman, J. E. J., Saunders, R., Aguirre, E., Davies, J., & Moncrieff, J. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116497 · Cited by 24
Antidepressant Discontinuation Syndrome
Rolston, C. D. (2018) · Springer eBooks · doi:10.1007/978-3-319-57111-9_9175 · Cited by 22
Vintage treatments for PTSD: A reconsideration of tricyclic drugs
Davidson, J. R. T. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565143 · Cited by 20
The meaning profiles of anxiety and depression: similarities and differences in two age groups
Kreitler, S. (2017) · Cognition & Emotion · doi:10.1080/02699931.2017.1311248 · Cited by 20
Safer, D. J. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000564 · Cited by 19
Pharmacological treatment of depression in women with breast cancer: a systematic review
Andersen, L. T., Hansen, M. V., Rosenberg, J., & Gögenür, I. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2708-6 · Cited by 19
Teixeira, M. Z. (2012) · Cited by 17
Silexan does not cause withdrawal symptoms even when abruptly discontinued
Gastpar, M., Müller, W. E. G., Volz, H., Möller, H. ‐., Schläfke, S., Dienel, A., & Kasper, S. F. (2017) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2017.1301488 · Cited by 18
Specificities of Treatment in Pediatric Obsessive-Compulsive Disorder
Flament, M. F., Geller, D., Irak, M., & Blier, P. (2007) · CNS Spectrums · doi:10.1017/s1092852900002509 · Cited by 17
Maniadakis, N., Kourlaba, G., Mougiakos, T., Chatzimanolis, I., & Jönsson, L. (2013) · BMC Health Services Research · doi:10.1186/1472-6963-13-173 · Cited by 17
Arakawa, R., Tateno, A., Kim, W., Sakayori, T., Ogawa, K., & Okubo, Y. (2016) · Psychiatry Research: Neuroimaging · doi:10.1016/j.pscychresns.2016.03.006 · Cited by 16
Schneider, M. L., Larson, J. A., Rypstat, C. W., Resch, L. M., Roberts, A. D., & Moore, C. F. (2013) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.12151 · Cited by 16
Silexan in anxiety, depression, and related disorders: pharmacological background and clinical data
Kasper, S. F., & Eckert, A. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01923-8 · Cited by 17
Pharmakotherapie von Angsterkrankungen – leitliniengerechte Therapie und Neuentwicklungen
Zwanzger, P., Singewald, N., & Bandelow, B. (2021) · Der Nervenarzt · doi:10.1007/s00115-020-01051-3 · Cited by 15
Characteristics of Escitalopram Discontinuation Syndrome: A Preliminary Study
Yasui-Furukori, N., Hashimoto, K., Tsuchimine, S., Tomita, T., Sugawara, N., Ishioka, M., & Nakamura, K. (2016) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000139 · Cited by 13
Why benzodiazepines are not going away: Commentary on… Benzodiazepines for Anxiety Disorders
Tyrer, P. (2012) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.111.009209 · Cited by 12
Pharmacological Treatment of Anxiety Disorders
Baldwin, D. S., & Brandish, E. K. (2014) · Wiley eBooks · doi:10.1002/9781118775349.ch43 · Cited by 13
Self-citationNinan, P. T., Musgnung, J. J., Messig, M., Buckley, G., Guico‐Pabia, C. J., & Ramey, T. S. (2015) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.14m01715 · Cited by 11
Foco, E. (2016) · Cited by 10
Extended-release formulation of venlafaxine in the treatment of post-traumatic stress disorder
Pae, C., Lim, H. K., Ajwani, N., Lee, C., & Patkar, A. A. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.6.603 · Cited by 10
Davies, J., & Read, J. (2019) · Addictive Behaviors · doi:10.1016/j.addbeh.2019.01.026 · Cited by 9
Perez, T. M., Glue, P., Adhia, D. B., Navid, M. S., Zeng, J., Dillingham, P., Smith, M., Niazi, I. K., Young, C. K., & De Ridder, D. (2022) · Trials · doi:10.1186/s13063-022-06863-z · Cited by 8
“The DESS has been used for the assessment of treatment-related sideeffects in ID populations [310, 311] and, recently, has been employed to monitor adverse-effects specifically associated with NFB therapy [312].”
MethodEvidence on antidepressant withdrawal: an appraisal and reanalysis of a recent systematic review
Moncrieff, J., Hobday, H., Sørensen, A., Read, J., Plöderl, M., Hengartner, M. P., Kamp, C. B., Jakobsen, J. C., Juul, S., Davies, J., et al. (2025) · Psychological Medicine · doi:10.1017/s0033291725100652 · Cited by 11
Similia similibus curentur: o princípio de cura homeopático fundamentado na farmacologia moderna
Teixeira, M. Z. (2013) · Revista de Medicina · doi:10.11606/issn.1679-9836.v92i3p183-203 · Cited by 13
Pharmacological Treatment of Anxiety Disorders in Children and Adolescents
Birmaher, B. B., & Sakolsky, D. J. (2012) · Wiley eBooks · doi:10.1002/9781118315088.ch11 · Cited by 9
Hydroxyzine for generalised anxiety disorder
Guaiana, G., Barbui, C., Churchill, R. C., Cipriani, A., & McGuire, H. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006815 · Cited by 9
Padoei, F., Mamsharifi, P., Hazegh, P., Boroumand, H., Ostadmohammady, F., Abbaszadeh‐Mashkani, S., Banafshe, H. R., Matini, A. H., Ghaderi, A., & Dehkohneh, S. G. (2022) · Brain and Behavior · doi:10.1002/brb3.2823 · Cited by 8
Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression
Gartlehner, G., Hansen, R. A., Morgan, L. C., Thaler, K. J., Lux, L. J., Noord, M. V., Mager, U., Gaynes, B. N., Thieda, P., Strobelberger, M., et al. (2011) · Cited by 8
Evidence-based pharmacotherapy of generalized anxiety disorder
Baldwin, D. S., Waldman, S., & Allgulander, C. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9780511910395.008 · Cited by 8
Self-citationSelective Serotonin Reuptake Inhibitors (SSRIs)
Sakolsky, D. J., & Birmaher, B. B. (2012) · Wiley eBooks · doi:10.1002/9781119958338.ch8 · Cited by 9
Hidden Costs: The Clinical and Research Pitfalls of Mistaking Antidepressant Withdrawal for Relapse
Horowitz, M. A., & Davies, J. (2024) · Psychotherapy and Psychosomatics · doi:10.1159/000542437 · Cited by 7
The importance of long-term tolerability in achieving recovery
Baldwin, D. S. (2006) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651500600552552 · Cited by 7
Self-citationDiffering antidepressant maintenance methodologies
Safer, D. J. (2017) · Contemporary Clinical Trials · doi:10.1016/j.cct.2017.07.021 · Cited by 8
Gilani, M., Abak, N., & Saberian, M. (2024) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2024.173897 · Cited by 6
Psychedelic assisted therapy for major depressive disorder: Recent work and clinical directions
McCartney, A., McGovern, H. T., & Foe, A. D. (2022) · Journal of Psychedelic Studies · doi:10.1556/2054.2022.00211 · Cited by 13
Anxiolytic-Like Effect of Cymbopogon Citratus (Lemongrass) Essential Oil
Alvarado-García, P. A. A., Vásquez, M. R. S., Cerquín, L. E. R., Benites, S. M., Romero, T. L. C., & Ramírez-Roca, E. G. (2023) · Pharmacognosy Journal · doi:10.5530/pj.2023.15.136 · Cited by 6
Chokkakula, S., Yang, H., Al-Masri, A. A., Zhang, Y., Naveen, B., & Yang, B. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1737113 · Cited by 5
Entstehung, Merkmale, Prävention und Behandlung von Absetzphänomenen
Brandt, L., Henssler, J. F., & Gutwinski, S. (2020) · InFo Neurologie + Psychiatrie · doi:10.1007/s15005-020-1293-6 · Cited by 4
Agomelatine in the treatment of mood and anxiety disorders
Baldwin, D. S., & Lopes, A. T. (2010) · British Journal of Hospital Medicine · doi:10.12968/hmed.2010.71.3.46979 · Cited by 4
Self-citationAntidepressant Discontinuation Syndrome
Rolston, C. D. (2017) · Springer eBooks · doi:10.1007/978-3-319-56782-2_9175-1 · Cited by 4
Metadata
- Authors
- Baldwin, D. S., Montgomery, S. A., Nil, R., & Lader, M.
- Affiliations
- University of Southampton (GB)
- Imperial College London (GB)
- University of London (GB)
- Corresponding author
- Baldwin, David S.
- Venue
- The International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-12-19
- Volume
- 10
- Issue
- 01
- Pages
- 73
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- OpenAlex
- W2053043565
- Cited by
- 140
- References
- 22
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 7 · 2023: 7 · 2022: 8 · 2021: 7 · 2020: 4 · 2019: 5 · 2018: 5 · 2017: 9 · 2016: 4 · 2015: 7 · 2014: 8 · 2013: 10 · 2012: 9
- FWCI
- 3.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Funders
- H. Lundbeck A/S
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- escitalopram, venlafaxine, paroxetine, major depressive disorder, social anxiety disorder, generalized anxiety disorder, antidepressant discontinuation, treatment duration
- MeSH terms
- Venlafaxine Hydrochloride, Adult, Anxiety Disorders, Cyclohexanols, Major Depressive Disorder, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Substance Withdrawal Syndrome, Time Factors, Citalopram, Treatment Outcome, Paroxetine, Antidepressive Agents, Second-Generation, Withholding Treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
